European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome

  • STATUS
    Recruiting
  • End date
    Jan 9, 2035
  • participants needed
    500
  • sponsor
    University Hospital Goettingen
Updated on 9 May 2021

Summary

The hereditary type IV collagen disease Alport syndrome inevitably leads to end-stage renal disease. Currently there are no therapies known to improve outcome. Our non-interventional, observational study investigates, if medications such as ACE-inhibitors can (1) delay time to dialysis and (2) improve life-expectancy within three generations of Alport-families in Europe.

Description

Early diagnosis in children with Alport syndrome (AS) with isolated hematuria opens a "window of opportunity" for early intervention. Currently there are no causal therapeutic options which are proven to delay renal failure in AS. ACE-inhibition (ACEi) has been shown to reduce proteinuria in Alport patients and to delay renal failure in Alport-mice suggesting it may be of value as an effective treatment to delay renal failure in humans. To test this we established the European Alport Registry to collect data over several generations of Alport families across Europe. Small children with AS first develop microscopic hematuria, proceeding to microalbuminuria, overt proteinuria, impaired renal function and end up with end stage renal disease. These different steps of disease enabled us to assess if earlier introduction of ACE-inhibition at earlier degrees of disease is more effective than later therapy in delaying the time to dialysis and improving life-expectancy.

Heterozygous COL4A3/COL4A4 mutations result in the phenotype "familial benign hematuria" or "thin basement membrane nephropathy" (TBMN). Affected subjects typically present with hematuria. Having longtime been regarded as "benign" familial hematuria, those patients might have an increased risk to develop severe renal impairment - comparable to the findings in female XLAS carriers (see above). TBMN is not a rare disease, as at least 1% of the population is affected.

For the first time, the present study compares the risk of renal impairment, end stage renal disease and premature death in between heterozygous carriers of XLAS and of ARAS mutations. Additionally, the nephroprotective effect of RAAS-blockade in patients with heterozygous Alport-mutations is evaluated.

Details
Condition Collagen disease, Collagen Vascular Diseases, Alport's Syndrome, Nephritis, Nephritis, Collagen Vascular Diseases, Hereditary Kidney Disease, Pediatric Kidney Disease, Thin Basement Membrane Disease, Familial Benign Hematuria
Treatment Spironolactone, Paricalcitol, ACE-inhibitor, AT1-inhibitor, HMG-Coenzyme inhibitor (statin)
Clinical Study IdentifierNCT02378805
SponsorUniversity Hospital Goettingen
Last Modified on9 May 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

The diagnosis of Alport syndrome (AS) was proven by kidney biopsy or mutation
analysis (or both). Patients were included if they were affected males with
X-linked AS or patients with genetically proven homozygous autosomal AS
Patients were excluded if they did not give informed consent or the diagnosis
was suspected but not confirmed
The diagnosis of the heterozygous status was proven by (1) mutation analysis
or (2) kidney biopsy plus genetic consultation for decision in between XLAS or
ARAS inheritance (including a conclusive genealogic tree and/or linkage
analysis). Patients were excluded if they were affected males with XLAS or
patients with genetically proven homozygous ARAS. Patients were excluded if
they did not give informed consent or the diagnosis was suspected but not
confirmed or if they donated a kidney (living donor to affected family
member)

Exclusion Criteria

The diagnosis of Alport syndrome (AS) was proven by kidney biopsy or mutation
analysis (or both). Patients were included if they were affected males with
X-linked AS or patients with genetically proven homozygous autosomal AS
Patients were excluded if they did not give informed consent or the diagnosis
was suspected but not confirmed
The diagnosis of the heterozygous status was proven by (1) mutation analysis
or (2) kidney biopsy plus genetic consultation for decision in between XLAS or
ARAS inheritance (including a conclusive genealogic tree and/or linkage
analysis). Patients were excluded if they were affected males with XLAS or
patients with genetically proven homozygous ARAS. Patients were excluded if
they did not give informed consent or the diagnosis was suspected but not
confirmed or if they donated a kidney (living donor to affected family
member)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note